Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H12N2O3.ClH |
| Molecular Weight | 220.653 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1(CC)C(=O)NC(=O)NC1=O
InChI
InChIKey=SACKVYGWWZDWQS-UHFFFAOYSA-N
InChI=1S/C8H12N2O3.ClH/c1-3-8(4-2)5(11)9-7(13)10-6(8)12;/h3-4H2,1-2H3,(H2,9,10,11,12,13);1H
Barbital, the one of the series of barbiturates, has hypnotic, sedative, and anticonvulsant properties and used under the trade name Veronal. It calmed manic patients and helped melancholic patients to sleep and was an effective inducer of sleep in insomniacs, but at the same time compound could induced dependence. It was substituted by the butyl analog, butobarbital, which was three times stronger and its period of action was much shorter due to its lipophilicity. Barbital is a ligand of GABA-receptor complex and in addition, it could have another target, a creatine kinase.
CNS Activity
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
300 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3860 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Condition: drug withdrawal Age Group: 19 years Sex: M Population Size: 1 Sources: |
Other AEs: Coma... |
250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
Other AEs: Dizziness, Drug intoxication... Other AEs: Dizziness Sources: Drug intoxication Euphoric Tiredness |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Coma | 5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Condition: drug withdrawal Age Group: 19 years Sex: M Population Size: 1 Sources: |
|
| Dizziness | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
| Drug intoxication | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
| Euphoric | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
| Tiredness | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Promotion by sodium barbital of renal cortical and transitional cell tumors, but not intestinal tumors, in F344 rats given methyl(acetoxymethyl)nitrosamine, and lack of effect of phenobarbital, amobarbital, or barbituric acid on development of either renal or intestinal tumors. | 1989 Jan |
|
| Induction of CYP2B1 mediated pentoxyresorufin O-dealkylase activity in different species, sex and tissue by prototype 2B1-inducers. | 1995 Mar 30 |
|
| Stability of thiopental and pentobarbital in human plasma determined with a new easy and specific gas chromatography-mass spectrometry assay. | 1999 Aug |
|
| Determination of barbiturates in urine by micellar liquid chromatography and direct injection of sample. | 1999 Nov |
|
| Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. | 2002 Nov 4 |
|
| Supramolecular synthons based on N-H...N and C-H...O hydrogen bonds. Crystal engineering of a helical structure with 5,5-diethylbarbituric acid. | 2002 Sep 7 |
|
| Biochemical mechanism of the effect of barbital on rifamycin B biosynthesis by Amycolatopsis mediterranei (M18 strain). | 2003 |
|
| Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment. | 2005 Nov |
|
| Binding of small guest molecules to multivalent receptors. | 2005 Oct 14 |
|
| Heme oxygenase, aminolevulinate acid synthetase and the antioxidant system in the brain of mice treated with porphyrinogenic drugs. | 2005 Oct 3 |
|
| Carbonic anhydrase in Tectona grandis: kinetics, stability, isozyme analysis and relationship with photosynthesis. | 2006 Aug |
|
| Floridoside extracted from the red alga Mastocarpus stellatus is a potent activator of the classical complement pathway. | 2008 |
|
| Variability and action mechanism of a family of anticomplement proteins in Ixodes ricinus. | 2008 Jan 2 |
|
| Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. | 2008 Nov |
|
| Biomass production potential of a wastewater alga Chlorella vulgaris ARC 1 under elevated levels of CO₂and temperature. | 2009 Feb |
|
| Complement consumption in children with Plasmodium falciparum malaria. | 2009 Jan 9 |
|
| The glyceraldehyde-3-phosphate dehydrogenase and the small GTPase Rab 2 are crucial for Brucella replication. | 2009 Jun |
|
| Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases. | 2010 Aug 20 |
|
| Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. | 2010 Jun 7 |
Patents
Sample Use Guides
It was reported the action of sodium barbital as an inhibitor of rabbit-muscle creatine kinase (CK), which plays a significant role in energy homeostasis in the muscles. The activity of CK underwent a rapid decrease when the concentration of sodium barbital was increased to 8 mmol/L, and the residual activity was about 35% of then active CK. The activity of CK dropped slowly until it was almost 0 when the concentration of sodium barbital was increased to 125 mmol/L. These results indicated that sodium barbital might function as an inhibitor of CK.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
22163315
Created by
admin on Sat Dec 16 18:30:11 GMT 2023 , Edited by admin on Sat Dec 16 18:30:11 GMT 2023
|
PRIMARY | |||
|
23851-27-6
Created by
admin on Sat Dec 16 18:30:11 GMT 2023 , Edited by admin on Sat Dec 16 18:30:11 GMT 2023
|
PRIMARY | |||
|
48Q3695ASR
Created by
admin on Sat Dec 16 18:30:11 GMT 2023 , Edited by admin on Sat Dec 16 18:30:11 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
